Hospitals need a shortlist as cardiology AI clearances hit 225

The FDA’s cardiology AI pipeline is no longer the hard part. The hard part is choosing what to deploy, where to deploy it, and who owns it once it’s live.

An FDA list update released June 16 and covered by Cardiovascular Business put the scale in black and white: 1,524 FDA-cleared AI algorithms in total, with cardiology remaining the No. 2 specialty behind radiology. Cardiology sits at 146 algorithms “listed specifically under cardiology,” but rises to 225 when cardiovascular imaging tools categorized elsewhere are counted, according to Cardiovascular Business.

That number matters operationally because it moves AI purchasing from a one-off “pilot a tool” mindset to portfolio management. Hospitals now face dozens of cleared options touching cath lab imaging, ECG interpretation, echocardiography quantification, and remote monitoring, each landing on different teams and different contracts.

The new benchmark: 225 cleared cardiology algorithms, but split across categories

Cardiovascular Business, citing the FDA’s updated inventory, broke out the specialty distribution as of March 30, 2026 (with the list released June 16): radiology at 1,163, cardiology at 146, neurology at 69, anesthesiology at 26, gastroenterology and urology at 24, and a long tail across other specialties.

For health system CIOs and clinical engineering leaders, the immediate lesson is classification. A cardiology service line committee that only tracks “cardiology” SKUs will miss a meaningful chunk of cardiovascular AI that is cleared and marketed as imaging. Cardiovascular Business’ own framing, 225 when cardiovascular imaging is included, is a cleaner planning baseline for governance and budgeting because it reflects how procurement actually encounters these products: through imaging, monitoring, and procedural platforms.

Clearances are landing in four places that hit IT and ops differently

The June 2026 cardiology clearance list compiled by Cardiovascular Business offers a snapshot of how AI is being put to work across cardiovascular care. It covers remote monitoring software such as Boston Scientific’s BodyGuardian Remote Monitoring System (BGRMS v3.0), echo measurement and navigation updates including Philips’ EchoNavigator R5.0, and image assessment tools across multiple modalities. Cardiovascular Business also pointed to use cases ranging from improving angiography images and providing in-lab cath guidance, to guidance during EP ablation procedures, and automated echocardiography quantification.

Those categories look similar on a spreadsheet, “AI for cardiology,” but they behave very differently in production. Remote monitoring tools raise questions about alert routing, staffing coverage, and whether the output goes into the EHR or stays in a vendor portal. Cath lab and imaging guidance tools raise latency, workstation, and modality integration requirements. Echo quantification tools change sonographer workflows and reading protocols, which is often where adoption succeeds or dies.

A 2025 review of randomized controlled trials evaluating AI in cardiology and related areas, available via PubMed Central, helps explain why health systems often stall at implementation: evidence quality and endpoints vary widely across studies. That doesn’t negate value. It does mean a buyer needs to define which outcome will be measured locally and what operational change is required to achieve it.

Vendor entry is continuing, and funding is following clearance

The FDA list is not just back-catalogue accounting. New vendors are still coming into the market with cleared products and fresh capital.

In a July 6, 2026 Cardiovascular Business newsletter, the outlet highlighted Pathway Labs, an AI company founded by cardiologist Pierre Elias, reporting that it gained FDA clearance and raised $8.5 million. The combination is a signal for hospital buyers: expect more newly cleared offerings that have not yet built deep implementation track records, but are quickly moving into commercialization.

That changes diligence. When a vendor pairs a new clearance with new funding, the practical question is less “will they exist next year?” and more “what will they actually staff?” For providers, the cost line that sneaks up is not the license, it’s the integration work, clinical champions, and protocol updates that convert a cleared algorithm into a durable clinical service.

A six-year breadcrumb trail: what AliveCor suggests about update cadence

AliveCor shows how long the cardiology AI product cycle can run, and why update cadence belongs in procurement conversations. Healio Cardiology reported in November 2020 that AliveCor announced 510(k) clearance for its next-generation AI algorithms for ECG interpretation on a personal ECG device. Cardiovascular Business’ June 2026 clearance roundup listed AliveCor again with “Corvair Monza,” indicating continued regulatory activity years later.

For hospital IT and clinical leadership, this is a quiet reminder: even when AI starts in consumer or ambulatory contexts, it can evolve into adjacent clinical products and refreshed clearances. That evolution can be good news for capability. It can also create version sprawl if departments buy tools independently and later try to consolidate.

Where this lands in hospital sourcing and governance this budget cycle

Cardiology’s clearance volume is now high enough that health systems can treat it like imaging IT: standardize intake, define technical requirements, and stop approving one-off exceptions. The FDA list covered by Cardiovascular Business provides the market map. The operational work is building a shortlist your clinicians will actually use.

• For EHR and integration teams: for any cardiology AI tool under review, require a dataflow diagram that shows where inputs come from (modality, device, or ECG system) and where outputs land (EHR, PACS, cath lab system, or vendor portal). If the vendor cannot show this, the pilot will stall.
• For service line and nursing leadership: classify the tool by operational burden, especially alert volume and coverage requirements for remote monitoring products such as Boston Scientific’s BodyGuardian, which Cardiovascular Business noted uses AI for arrhythmia detection and monitoring. Decide upfront who owns the inbox.
• For procurement and legal: add an “update and revalidation” clause. AliveCor’s multi-year clearance trail across Healio (2020) and Cardiovascular Business (2026) is a concrete reason to ask how model updates are delivered, tested, and communicated, and whether an update triggers retraining or protocol changes.
• For cardiology chiefs and quality teams: pick one measurable endpoint for each AI deployment and a timeline to judge it. PubMed’s review of randomized trials is a reminder that evidence varies, so local measurement plans need to be explicit.